FDA’s Decision Boosts Accelerate Diagnostics (AXDX); Analysts See Upside in The GEO Group (GEO)

accelerate_diagnostics_axdx

Shares of Accelerate Diagnostics Inc. (Nasdaq:AXDX) climbed over 16% to touch a new 52-week high in after-hours trading Thursday as the U.S. Food and Drug Administration (FDA) said that it has decided to allow marketing of its PhenoTest BC Kit – a multiplexed in vitro diagnostic test for use with the company’s Pheno System – for identification and antibiotic susceptibility testing of organisms that cause bloodstream infections.

AXDX stock finished the regular session in positive territory by 1.23% (or +$0.30) at $24.75 with a total volume of 147,300 shares traded.

Accelerate Diagnostics, which provides solutions for the diagnosis of serious infections, has 51.44M shares outstanding. At close on Thursday, the vitro diagnostics company had a market capitalization of $1.29B and AXDX stock one-year range was between $10.87 and $28.50 per share

*

the_geo_group_geo

Analysts at Canaccord Genuity reiterated a Buy rating and raised their price target on The GEO Group Inc. (NYSE:GEO) shares from $43.00 to $52.00, suggesting a potential upside of 9.77% from the stock’s closing price on Thursday of $47.37

A couple days ago, GEO reported in its financial results fourth-quarter 2016 revenues of $566.6 million, a 13.29@ increase year over year, and net income of $49.4 million, or $0.66 per diluted share, compared to net income of $44.1 million, or $0.59 per diluted share in the same period the prior year.

The GEO Group, which provides government-outsourced services specializing in the management of correctional, detention, and re-entry facilities, has 75.01M shares outstanding, market capitalization (intraday) of $3.55B and GEO stock 52-week range is from $16.26 to $47.87 per share.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/